News

AstraZeneca buys Omthera
Enlarge image

BusinessUKSwedenIrelandGermanyNorway

AstraZeneca buys Omthera

29.05.2013 - AstraZeneca has filled its pipeline with a Phase III fish oil cardioprotective drug, taking over Omthera Pharmaceuticals for $443m.

The British-Swedish drug giant will pay Omthera $12.70 per share, or approximately $323 million, a premium of 88% to Omthera's closing price on Friday. In addition, Omthera shareholders will get "contingent value rights" (CVRs) of up to approximately $4.70 per share, or $120 million in total, depending on the success of Omthera's experimental fish oil-derived medicine Epanova to treat patients with very high triglyceride levels. Epanova is a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 

The expansion into the cardiovascular market pitches AstraZeneca into competition with rivals including Irish Amarin, British Glaxo SmithKline that is marketing the $917m fish-oil derived medicine Lovaza or Geman BASF, who has taken over Norwegian Pronova. Omthera's drug is ready to be filed for US approval and could be combined with AstraZeneca's cholesterol fighter Crestor.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/astrazeneca-buys-omthera.html

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%
  • ADDEX3.32 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%

TOP

  • SANTHERA94.75 CHF47.8%
  • FORMYCON8.30 EUR19.9%
  • EPIGENOMICS3.61 EUR14.6%

FLOP

  • EVOTEC3.12 EUR-16.8%
  • MEDIGENE3.98 EUR-15.7%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA94.75 CHF2524.7%
  • CO.DON2.71 EUR218.8%
  • PAION2.71 EUR155.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • 4SC1.16 EUR-40.5%
  • MERCK KGAA68.05 EUR-38.7%

No liability assumed, Date: 14.09.2014